Cooper Companies, INC

CooperCompanies achieved record Q2 2026 revenue of $1.082 billion, though GAAP earnings were impacted by a $271.6 million litigation-related charge.

CooperCompanies announced the appointment of Paul Keel as an independent director to its Board, effective July 1, 2026, and as a member of the Audit Committee.

The Cooper Companies, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

CooperCompanies announced robust first quarter 2026 financial results, exceeding expectations and leading to an upward revision of its full-year earnings and free cash flow guidance.

The Cooper Companies, Inc. has amended its term loan and revolving credit agreements, extending the maturity of $950 million in term loans to 2031 and increasing its incremental debt capacity.

CooperCompanies has appointed Walter M. Rosebrough, Jr. to its Board of Directors and entered into a cooperation agreement with activist investor Browning West, LP.

The Cooper Companies reported an 8% revenue increase to $1.08 billion but swung to a net loss due to a $271.6 million litigation accrual related to a surgical product recall.

The Cooper Companies, Inc. reported a significant increase in net income and diluted EPS for the first quarter of fiscal 2026, driven by strong performance across both CooperVision and CooperSurgical segments.

The Cooper Companies reported mixed third-quarter results with strong CooperVision sales growth offset by a significant operating loss in CooperSurgical due to product line write-offs.

The Cooper Companies, Inc. reported increased net sales and operating income for the second quarter and first six months of fiscal 2025, driven by strong performance in both CooperVision and CooperSurgical segments, despite a material weakness in internal controls and a higher effective tax rate impacting quarterly net income.

The Cooper Companies' Q1 2025 results show increased revenue and operating income, driven by growth in CooperVision and CooperSurgical, despite unfavorable foreign exchange impacts and a previously identified material weakness in IT controls.

The Cooper Companies reported a solid third quarter for fiscal year 2024, with increased net sales and operating income across both its CooperVision and CooperSurgical segments.

The Cooper Companies reported a 5% increase in fiscal year 2025 net sales to $4.09 billion, driven by CooperVision, but saw a 3% decline in operating income and a 63% drop in CooperSurgical's operating income.

The Cooper Companies, a global medical device company, released its 10-K filing for fiscal year 2024, highlighting growth in both its CooperVision and CooperSurgical segments while navigating economic and regulatory complexities.

Paul Keel, a Director at The Cooper Companies, Inc., reported the acquisition of 2,814 Restricted Stock Units.

Director Walter M. Rosebrough Jr. acquired 832 shares of The Cooper Companies, Inc. common stock through the vesting of restricted stock units.

Robert S. Weiss, a Director at The Cooper Companies, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

Maria Rivas, a Director at The Cooper Companies, Inc., reported the acquisition of 3,322 shares of common stock on April 1, 2026, through a transaction valued at $0.00.

Cooper Companies Director Colleen Jay reported a transaction involving the acquisition of 3,322 shares of common stock.

Barbara Carbone, a Director at The Cooper Companies, Inc., has reported transactions involving the acquisition of common stock and restricted stock units.

The Cooper Companies, Inc. has filed definitive additional materials with the SEC, indicating a definitive proxy statement.

CooperCompanies delivered double-digit full-year earnings growth and exceeded free cash flow expectations in fiscal 2025, strengthening its foundation for sustainable growth and expanding its share repurchase program.

The Cooper Companies, Inc. has filed a definitive proxy statement with the SEC.

CooperCompanies' 2025 proxy statement outlines the company's strategic focus on market share gains, profitability, and long-term growth, while also detailing executive compensation practices and corporate governance policies.

Vanguard Capital Management has reported a beneficial ownership of 7.51% in Cooper Companies Inc. (The) common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cooper Cos Inc/The following an internal realignment that disaggregates reporting to its subsidiaries.

Capital World Investors has reported a 5.5% beneficial ownership stake in Cooper Companies, holding over 10.9 million shares of common stock.

BlackRock, Inc. has filed an Amendment No. 16 to its Schedule 13G, disclosing a 7.1% passive beneficial ownership stake in Cooper Companies Inc. as of March 31, 2025.